logo
Chronic but not powerless, why your estate plan deserves a seat at the doctor's office

Chronic but not powerless, why your estate plan deserves a seat at the doctor's office

Yahoo4 days ago
Juggling modern families, demanding careers, shifting politics, doctors' appointments, insurance paperwork, and copays, and everything society throws at us is already a full-time job. Add a chronic condition — like HIV, cancer, multiple sclerosis, or anything that requires ongoing care — and the balancing act becomes something closer to running the gauntlet.
It's a lot. And most people don't get it, especially when your condition is invisible. Or stigmatized. Or both.
But here's the truth I've learned from working with clients living with chronic illness: The strongest among us don't just "push through." They take control — not just of their health, but of their financial and estate plans. Because the minute life gets complicated, the cost of not planning skyrockets.
I've worked with people who've beaten cancer, who live with HIV, juggle therapy appointments and their kids' soccer schedule, all while trying to make sense of their financial goals and dreams. What they have in common isn't just resilience. It's that quiet, sobering moment when they realize: "I need a plan."
That moment doesn't happen in every financial advisor's or lawyer's office. Sometimes it hits when a hospital intake form asks, "Do you have a healthcare power of attorney?" Or when someone close to them ends up in a medical crisis with no documents and no clarity. That's when the gravity sinks in: chronic illness doesn't wait for your financial life to be in order.
And here's the thing most financial professionals won't say out loud: if you're living with a chronic condition, you can't afford not to plan. Not out of fear, but out of self-respect, love for the people in your life, and power over your own story.
Let's start with the part everyone dreads: estate planning.
Most people avoid it because it feels like preparing for death. But if you're living with a chronic condition, it's not about dying — it's about protecting your autonomy while you're alive. If your health situation could ever leave you unable to speak for yourself, you need documents that do the talking:
Healthcare Power of Attorney: Choose someone you trust (really trust) to make medical decisions on your behalf.
Living Will or Advance Directive: Spell out your wishes clearly. Whether it's aggressive treatment or comfort-focused care, this is where your voice lives if you can't speak.
HIPAA Authorization: Make sure the right people — especially your partner or chosen family — can access your medical information.
Durable Financial Power of Attorney: Someone has to pay the rent and manage your finances if you're in the hospital. Choose wisely. (No offense to your cousin with 13 credit cards and a sneaker reselling habit.)
Revocable Living Trust: If you own assets — especially if you're unmarried or estranged from family — this helps ensure your belongings go where you want them to, without court interference.
For many in the LGBTQ+ community, chosen family plays a bigger role than blood relatives. But without legal documentation, the system doesn't care who actually showed up for you when it mattered. That's why these documents aren't just "recommended." They're essential.
And emotionally? This work can be heavy. For those who have faced rejection from family or institutions, it can resurface painful memories. But it's also one of the most potent acts of self-advocacy you can make.
This is about saying: This is who I trust. This is who I love. This is who gets a say.
This isn't about doomsday prepping. It's about giving yourself options, control, and flexibility — so your health doesn't dictate your financial future more than it has to.
Emergency Funds & Cash Flow
Even with insurance, chronic conditions come with unpredictable costs, including copays, travel expenses, and lost income due to time off work. Plan to have:
6–12 months of essential expenses saved
Short- and long-term disability coverage (through work or individually)
A clear understanding of what your insurance does — and doesn't — cover
This isn't paranoia. It's confidence.
Insurance (Yes, It's Still Worth Talking About)
Most people think life insurance is obvious, but disability insurance is also critical if you rely on your income, and most of us do. But if you're managing a chronic condition, you may face exclusions or outright denials. That's frustrating, but not a dead end.
There are still pathways to protecting your family:
Group disability coverage through your employer or professional associations may not require medical underwriting.
Employer-sponsored life insurance — often guaranteed issue and a great base layer.
Life Insurance – many carriers now offer coverage for people living with conditions such as HIV, with recent advancements in treatment.
Survivorship policies if you're partnered and one partner is uninsurable alone.
Leaning on your partner's benefits, primarily if they work for an inclusive employer that allows domestic partner enrollment, even if not legally married.
One HR form could mean access to coverage you wouldn't qualify for on your own.
Rethinking Retirement
Chronic illness can shift your timeline. Maybe you want to retire early. Perhaps you need more liquidity. Maybe you want the flexibility to work part-time at 50 and focus on advocacy, art, or your own damn peace.
Traditional retirement accounts still matter and serve as the foundation. But if you're living with a chronic condition, you might want more flexibility than a standard 401(k) offers. That's where diversification comes in. Think beyond just one type of account. Many of my clients benefit from having a mix of Roth, taxable brokerage accounts, and yes, even the trusty 401(k). The goal is to create options. Because life doesn't always follow a textbook timeline, and your money shouldn't be stuck in one either.
For individuals managing chronic conditions, the Health Savings Account (HSA) is the real MVP — or, to be honest, the GOAT.
If you qualify for one, an HSA is more than just a savings account. It's a triple-threat: money goes in tax-deductible, grows tax-free, and comes out tax-free when used for medical expenses. It's like having a backstage pass to cover the healthcare costs you already know are on the way.
And here's the bonus: after age 65, you can even use it for non-medical expenses without penalty. That flexibility makes it one of the most powerful tools in your financial toolkit, especially if healthcare will always be a line item in your budget.
Many clients I work with want to give back to the communities and causes that have helped them, including HIV research, mental health access, LGBTQ+ rights, hospice care, and housing justice.
That legacy can also be part of your financial plan.
Name a nonprofit as a beneficiary on a life insurance policy, IRA, or 401(k)
Use a donor-advised fund to give strategically during your lifetime
Include charitable bequests in your will or trust
This isn't just about reducing taxes. It's about using your resources to reflect your values. To say: This mattered to me. And I want it to continue.
Planning = Peace
Here's what I've seen over and over again: once the plan is in place, people breathe differently.
There's a lightness. A quiet confidence. A sense of relief that your care, your finances, and your legacy won't be dictated by courts, chaos, or people who don't actually know you.
If you're living with a chronic condition, you deserve more than just medical care. You deserve a plan that sees the whole you — your relationships, your resilience, and your right to decide what comes next.
So go ahead. Schedule the meeting. Sign the documents. Set the plan in motion. Then? Rest. Enjoy what makes you happy. Travel without "what-ifs." Live with confidence.
Because now — finally — you have a plan.
Voices is dedicated to featuring a wide range of inspiring personal stories and impactful opinions from the LGBTQ+ community and its allies. Visit Advocate.com/submit to learn more about submission guidelines. Views expressed in Voices stories are those of the guest writers, columnists, and editors, and do not directly represent the views of The Advocate or our parent company, equalpride.
This article originally appeared on Advocate: Chronic but not powerless, why your estate plan deserves a seat at the doctor's office
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Sickening' and ‘evil': Musk bashed for USAID cuts after study predicts millions could die
‘Sickening' and ‘evil': Musk bashed for USAID cuts after study predicts millions could die

Yahoo

time14 hours ago

  • Yahoo

‘Sickening' and ‘evil': Musk bashed for USAID cuts after study predicts millions could die

Medical experts and lawmakers are denouncing Elon Musk as cruel after a new study predicted that the billionaire's efforts to help the Trump administration dismantle the U.S. Agency for International Development could lead to more than 14 million deaths over the next five years. According to the analysis, published Monday in the medical journal The Lancet, programs funded by USAID prevented nearly 92 million deaths worldwide from 2001 through 2021. Researchers found that across 133 countries, the agency helped stop more than 25 million deaths from HIV/AIDS, about 11 million from diarrheal diseases, 8 million from malaria and nearly 5 million from tuberculosis. Using that data, experts calculated that 14 million people around the globe could die over the next five years because of the USAID cuts, including about 4.5 million children younger than 5. USAID became an agency of particular interest to Musk, as his so-called Department of Government Efficiency carried out President Donald Trump's mission to slash the federal budget. In February, Musk bragged on X that he 'spent the weekend feeding USAID into the wood chipper.' A month later, Secretary of State Marco Rubio announced the cancellation of 83% of USAID's programs, saying they did not serve 'the core national interests of the United States.' Rubio's move had an immediate effect, as NBC News reported: The action brought many overseas humanitarian efforts to a grinding halt, leading to the closings of food kitchens and health clinics in underserved countries and in some cases delaying or stopping the distribution of lifesaving medications, bed nets to ward off malaria, nutritional packets for starving children and chlorine tablets to disinfect dirty water. Samantha Power, who led USAID during the Biden administration, told CNN that the effects that Musk's cuts will have on global health are 'not something that any American should tolerate.' 'Efficiency, we're all for efficiency, but actually taking away programming that is saving lives … that's just devastating,' Power said. Timothy Caulfield, a professor of health law and science policy at the University of Alberta in Canada, called the prediction 'Sickening. Heartbreaking. Evil.' Rachel Clarke, an English physician specializing in severe illness, seemingly singled out Musk, attributing the estimated death toll to 'one man's cruelty & venality.' Congressional Democrats also shared their reactions to the study. 'Donald Trump's legacy: As many as 14 MILLION more deaths over the next five years thanks to USAID cuts made by him, Elon Musk, and his DOGE bros,' Sen. Dick Durbin of Illinois wrote on X. 'Absolutely shameful.' 'This administration's cruelty knows no bounds,' Rep. Pramila Jayapal of Washington wrote in her own post. This article was originally published on

Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)

Yahoo

time2 days ago

  • Yahoo

Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo® (lenacapavir), Gilead Sciences, Inc. (NASDAQ:GILD)'s injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in order to reduce the risk of sexually acquired HIV in adults and adolescents weighing a minimum of 35 kg. The company's Chief Executive added that this medicine is required to be given twice a year, and it has demonstrated strong outcomes in clinical studies, meaning it can transform HIV prevention. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. The approval of Gilead Sciences, Inc. (NASDAQ:GILD)'s New Drug Applications (NDAs) for Yeztugo was supported by data from Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by the company. In the US, Gilead Sciences, Inc. (NASDAQ:GILD) continues to work closely with insurers, healthcare systems, and other payers, targeting to ensure broad insurance coverage for Yeztugo. Furthermore, for eligible commercially insured individuals with commercial insurance, the company's Advancing Access® Co-Pay Savings Program is expected to reduce out-of-pocket costs to as low as zero dollars. Notably, HIV product sales saw an increase of 6% to $4.6 billion in Q1 2025 as compared to the same period in 2024. This was mainly driven by increased average realized price and demand. Impax Asset Management, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Gilead Sciences, Inc. (NASDAQ:GILD) (Health Care) the company is owned due to its role in solving evolving heath care challenges through the development of new medical treatments for conditions as chronic diseases are on the rise. The company also has one of the highest systematic ESG scores in the portfolio. Gilead reported better-than-expected quarterly results, largely driven by strong revenue from its HIV franchise. The company also provided an optimistic earnings guidance for the next fiscal year, helping provide defensiveness amid a flurry of volatility.' While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

Theratechnologies shares surge 25% amid $254m Future Pak takeover
Theratechnologies shares surge 25% amid $254m Future Pak takeover

Yahoo

time2 days ago

  • Yahoo

Theratechnologies shares surge 25% amid $254m Future Pak takeover

Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of the Canadian HIV-specialist biopharma. Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future milestones. Shares in Theratechnologies increased 25% at market open following the takeover announcement. The drugmaker has a market cap of $144.6m. The transaction, which will bring the currently Nasdaq-listed Theratechnologies back under private ownership, means Future Pak is paying a cash premium of 126% on the last closing share price for the biopharma. Theratechnologies has two products in the HIV arena that are approved by the US Food and Drug Administration (FDA), namely Egrifta (tesamorelin F8) and Trogarzo (ibalizumab-uiyk). Egrifta is approved to reduce excess visceral abdominal fat in adults with HIV and lipodystrophy while Trogarzo is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistance. Egrifta WR took over from Egrifta SV in March 2025, offering a more convenient formulation. Expected to close in Q4, the deal will close a sale process that has fluctuated over the past year. Future Pak's first attempt to acquire Theratechnologies was rebuffed in August 2024, with the biopharma deeming the $100m offer too low. Future Pak returned to the deal table in January 2025. Theratechnologies had already entered an exclusivity agreement with another potential acquirer, meaning Future Pak was once again turned away. Theratechnologies eventually opened the sale process to other parties, opening the door for a potential deal with the contract manufacturer. In April 2025, Future Pak tabled a $255 offer, which has now been accepted by the drugmaker. Theratechnologies reported 2024 revenue of $85.9m, a 5% increase from the $81.8m accumulated in 2023. Whilst the company reported a positive EBITDA for the year, it struggled with supply for Egrifta WR due to an issue with a contract manufacturer. Still, sales of the drug grew 12%, unlike Trogarzo, which dropped 8% due to 'competitive pressures' in the multidrug-resistant segment of the HIV market. 'This transaction is the result of a thorough and deliberate sale process aimed at maximising value for our shareholders,' stated Frank Holler, Theratechnologies' chair of the board of directors. 'Future Pak's interest in acquiring Theratechnologies represents a vote of confidence in the company we've built, recognising our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees.' Last year, Future Pak also made multiple unsuccessful attempts to acquire Vanda Pharmaceuticals, the developer of sleep disorder drug Hetlioz. Cycle Therapeutics ultimately won out, acquiring in a $466m deal. "Theratechnologies shares surge 25% amid $254m Future Pak takeover" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store